Numerous recent advances in the medications and technologies available to treat benign prostatic hyperplasia (BPH) raise many questions for practicing urologists seeking optimal therapies for their patients. In Management of Benign Prostatic Hypertrophy, a panel of internationally recognized expert clinicians and investigators in urology review the new treatments in the light of established urologic principles and tradition. The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5a-reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms, with special attention given to a more current understanding and treatment of postobstructive diuresis, a significant medical complication and frequent source of urologic consultation.
Grounded in the principles and hallmarks of urology, Management of Benign Prostatic Hypertrophy satisfies the needs of practicing urologists seeking a concise up-to-date interpretation and analysis of the many new therapies available for the treatment of BPH.

Klappentext

A concise, up-to-date review of the many new therapies available for the treatment of benign prostatic hypertrophy (BPH). The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5-a reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms. A perfect reference source for the practicing urologist seeking sound guidance on the best approach to his patients.

Inhalt

Prostate Anatomy and Causative Theories, Pathophysiology, and Natural History of Benign Prostatic Hyperplasia Jeffrey A. Stern, John M. Fitzpatrick, and Kevin T. McVary The Definition of Benign Prostatic Hyperplasia: Epidemiology and Prevalence Glenn S. Gerber Pathophysiology, Diagnosis, and Treatment of the Postobstructive Diuresis Chris M. Gonzalez Urodynamics and the Evaluation of Male Lower Urinary Tract Symptoms J. Quentin Clemens a-Adrenergic Antagonists in the Treatment of Benign Prostatic Hypertrophy-Associated Lower Urinary Tract Symptoms Ross A. Rames and David C. Horger 5a-Reductase Inhibitors Robert E. Brannigan and John T. Grayhack Transurethral Needle Ablation of the Prostate Timothy F. Donahue and Joseph A. Costa Transurethral Microwave Thermotherapy Jonathan N. Rubenstein and Kevin T. McVary Transurethral Incision of the Prostate Robert F. Donnell Interstitial Laser Coagulation and High-Intensity Focused Ultrasound for the Treatment of Benign Prostatic Hyperplasia Christopher M. Dixon Transurethral Resection of the Prostate Harris E. Foster, Jr. and Micah Jacobs Transurethral Vaporization of the Prostate Joe O. Littlejohn, Young M. Kang, and Steven A. Kaplan Treatment of Benign Prostatic Hyperplasia with Ethanol Injections, Water-Induced Thermotherapy, and Prostatic Urethral Luminal Stents Jay Y. Gillenwater Suprapubic Transvesical Prostatectomy and Simple Perineal Prostatectomy for the Treatment of Benign Prostatic Hyperplasia James M. Kozlowski, Norm D. Smith, and John T. Grayhack. Index.